142.58
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ILMN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$139.07
Aprire:
$139.04
Volume 24 ore:
1.33M
Relative Volume:
0.73
Capitalizzazione di mercato:
$21.57B
Reddito:
$4.39B
Utile/perdita netta:
$853.00M
Rapporto P/E:
25.88
EPS:
5.5097
Flusso di cassa netto:
$556.00M
1 W Prestazione:
+18.45%
1M Prestazione:
+11.62%
6M Prestazione:
+17.73%
1 anno Prestazione:
+91.31%
Illumina Inc Stock (ILMN) Company Profile
Nome
Illumina Inc
Settore
Industria
Telefono
(858) 202-4500
Indirizzo
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, WAT, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
ILMN
Illumina Inc
|
142.58 | 21.04B | 4.39B | 853.00M | 556.00M | 5.5097 |
|
TMO
Thermo Fisher Scientific Inc
|
472.95 | 173.46B | 45.20B | 6.87B | 6.75B | 18.19 |
|
DHR
Danaher Corp
|
174.92 | 123.60B | 24.78B | 3.68B | 5.29B | 5.1743 |
|
IDXX
Idexx Laboratories Inc
|
579.23 | 44.71B | 4.30B | 1.06B | 1.04B | 13.08 |
|
WAT
Waters Corp
|
349.53 | 33.65B | 3.77B | 449.25M | 516.49M | 8.7322 |
|
A
Agilent Technologies Inc
|
117.69 | 33.21B | 7.07B | 1.29B | 993.00M | 4.5355 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-12 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Reiterato | Citigroup | Neutral |
| 2025-02-28 | Downgrade | HSBC Securities | Buy → Hold |
| 2025-02-10 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2024-11-12 | Ripresa | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-08-28 | Aggiornamento | Argus | Hold → Buy |
| 2024-08-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Aggiornamento | TD Cowen | Hold → Buy |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-06-03 | Ripresa | Jefferies | Hold |
| 2024-01-16 | Downgrade | HSBC Securities | Buy → Hold |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-14 | Iniziato | Stephens | Overweight |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-12-12 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-11-10 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Iniziato | Bernstein | Underperform |
| 2023-07-05 | Ripresa | JP Morgan | Neutral |
| 2023-01-25 | Downgrade | Argus | Buy → Hold |
| 2023-01-05 | Iniziato | Scotiabank | Sector Perform |
| 2022-12-12 | Downgrade | Citigroup | Neutral → Sell |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-04 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-07-13 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Aggiornamento | Stifel | Hold → Buy |
| 2022-01-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Ripresa | Piper Sandler | Overweight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Aggiornamento | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Iniziato | Barclays | Underweight |
| 2020-12-22 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2020-10-13 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Downgrade | Stifel | Buy → Hold |
| 2020-09-22 | Downgrade | UBS | Buy → Neutral |
| 2020-09-21 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-21 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Downgrade | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2020-04-24 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2020-01-02 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Illumina Inc Borsa (ILMN) Ultime notizie
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
[144] ILLUMINA, INC. SEC Filing - Stock Titan
Global DNA Microarray Market is Predicted to Exhibit Remarkable Growth at a CAGR of ~7% by 2034 | DelveInsight - GlobeNewswire Inc.
Whole Exome Sequencing Market key players 2024-2031: Illumina, Inc., Centogene AG, Eurofins Scientific etc - openPR.com
Illumina Shareholder Alert - TMX Newsfile
Uber, Exxon Mobil, Illumina, Diamondback Energy: CNBC's 'Final Trades' - MSN
Epigenetics Market is expected to Hit US$ 7.10 Billion by 2033 | - openPR.com
Illumina, Inc. Q1 2026 Financial Report: Earnings, Revenue, Risk Factors & Forward-Looking Statements 18 24 37 - Minichart
Final Trades: Uber, Exxon, Illumina and Diamondback Energy - CNBC
Illumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab Products
Genomics Market size is anticipated to reach US$ 83.61 billion - openPR.com
Illumina (ILMN) Q1 2026 Earnings: Revenue Beat and Raised GuidanceNews and Statistics - IndexBox
Illumina, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ILMN) 2026-05-03 - Seeking Alpha
ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges - Yahoo Finance
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (ILMN), Moderna (MRNA) and Dexcom (DXCM) - The Globe and Mail
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
[10-Q] ILLUMINA, INC. Quarterly Earnings Report - Stock Titan
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up - Yahoo Finance
Canaccord cuts Illumina stock price target on competition concerns - Investing.com UK
Illumina, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Illumina, Inc. (NASDAQ:ILMN) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord cuts Illumina stock price target on competition concerns By Investing.com - Investing.com Canada
Illumina Q1 2026 earnings preview - MSN
Evercore ISI raises Illumina stock price target on strong results By Investing.com - Investing.com Canada
Evercore ISI raises Illumina stock price target on strong results - Investing.com
Florida Hospital Association adds Gaye Walker as communications VP - Florida Politics
ILMN SEC FilingsIllumina Inc 10-K, 10-Q, 8-K Forms - Stock Titan
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
MSN Money - MSN
Earnings Call Summary | Illumina(ILMN.US) Q1 2026 Earnings Conference - Moomoo
Illumina Q1 2026 slides: earnings beat on clinical strength, margins expand - Investing.com Canada
Illumina (NASDAQ:ILMN) Releases Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo News Malaysia
Illumina set to report earnings amid rising Roche competition - Investing.com
Illumina Q1 Earnings Call Highlights - Yahoo Finance
Illumina (ILMN) Q1 2026 Earnings Transcript - AOL.com
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises - Investing.com
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises By Investing.com - Investing.com South Africa
Transcript : Illumina, Inc., Q1 2026 Earnings Call, Apr 30, 2026 - marketscreener.com
Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026 - Yahoo Finance
Illumina lifts 2026 outlook and expands share buybacks - TipRanks
Illumina Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Outlook - marketscreener.com
(ILMN) Illumina Expects Fiscal 2026 Adjusted EPS Range $5.15-$5.30, vs. FactSet Est of $5.12 - marketscreener.com
Illumina: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (ILMN) Illumina, Inc. Posts Q1 Adjusted EPS $1.15 per Share, vs. FactSet Est of $1.05 - marketscreener.com
Illumina Inc Azioni (ILMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):